A Phase I, Open-label, Single Dose, Mass Balance Trial to Investigate Metabolism and Pharmacokinetics of BI 1291583 (C-14) Administered as Oral Solution in Healthy Male Subjects
Latest Information Update: 13 Jul 2023
At a glance
- Drugs BI 1291583 (Primary)
- Indications Bronchiectasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.
- 02 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 02 May 2023 Status changed from not yet recruiting to recruiting.